-
Something wrong with this record ?
Selective binding of tumor suppressor p53 protein to topologically constrained DNA: modulation by intercalative drugs
H. Pivoňková, P. Šebest, P. Pecinka, O. Tichá, K. Nemcová, M. Brázdová, EB. Jagelská, V. Brázda, M. Fojta
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acridines chemistry pharmacology MeSH
- Chloroquine chemistry pharmacology MeSH
- Doxorubicin chemistry pharmacology MeSH
- Intercalating Agents chemistry pharmacology MeSH
- Binding, Competitive MeSH
- Nucleic Acid Conformation drug effects MeSH
- Humans MeSH
- Tumor Suppressor Protein p53 chemistry metabolism MeSH
- DNA, Superhelical chemistry drug effects metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Selective binding of the wild type tumor suppressor protein p53 to negatively and positively supercoiled (sc) DNA was studied using intercalative drugs chloroquine (CQ), ethidium bromide, acridine derivatives and doxorubicin as a modulators of the level of DNA supercoiling. The p53 was found to lose gradually its preferential binding to negatively scDNA with increasing concentrations of intercalators until the DNA negative superhelix turns were relaxed. Formation of positive superhelices (due to further increasing intercalator concentrations) rendered the circular duplex DNA to be preferentially bound by the p53 again. CQ at concentrations modulating the closed circular DNA topology did not prevent the p53 from recognizing a specific target sequence within topologically unconstrained linear DNA. Experiments with DNA topoisomer distributions differing in their superhelix densities revealed the p53 to bind selectively DNA molecules possessing higher number of negative or positive superturns. Possible modes of the p53 binding to the negatively or positively supercoiled DNA and tentative biological consequences are discussed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025165
- 003
- CZ-PrNML
- 005
- 20170626103954.0
- 007
- ta
- 008
- 120816s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bbrc.2010.02.120 $2 doi
- 035 __
- $a (PubMed)20175992
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pivoňková, Hana $7 xx0104637 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Královopolská 135, 612 65 Brno, Czech Republic. hapi@ibp.cz
- 245 10
- $a Selective binding of tumor suppressor p53 protein to topologically constrained DNA: modulation by intercalative drugs / $c H. Pivoňková, P. Šebest, P. Pecinka, O. Tichá, K. Nemcová, M. Brázdová, EB. Jagelská, V. Brázda, M. Fojta
- 520 9_
- $a Selective binding of the wild type tumor suppressor protein p53 to negatively and positively supercoiled (sc) DNA was studied using intercalative drugs chloroquine (CQ), ethidium bromide, acridine derivatives and doxorubicin as a modulators of the level of DNA supercoiling. The p53 was found to lose gradually its preferential binding to negatively scDNA with increasing concentrations of intercalators until the DNA negative superhelix turns were relaxed. Formation of positive superhelices (due to further increasing intercalator concentrations) rendered the circular duplex DNA to be preferentially bound by the p53 again. CQ at concentrations modulating the closed circular DNA topology did not prevent the p53 from recognizing a specific target sequence within topologically unconstrained linear DNA. Experiments with DNA topoisomer distributions differing in their superhelix densities revealed the p53 to bind selectively DNA molecules possessing higher number of negative or positive superturns. Possible modes of the p53 binding to the negatively or positively supercoiled DNA and tentative biological consequences are discussed.
- 650 _2
- $a akridiny $x chemie $x farmakologie $7 D000166
- 650 _2
- $a kompetitivní vazba $7 D001667
- 650 _2
- $a chlorochin $x chemie $x farmakologie $7 D002738
- 650 _2
- $a superhelikální DNA $x chemie $x účinky léků $x metabolismus $7 D004278
- 650 _2
- $a doxorubicin $x chemie $x farmakologie $7 D004317
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interkalátory $x chemie $x farmakologie $7 D007364
- 650 _2
- $a konformace nukleové kyseliny $x účinky léků $7 D009690
- 650 _2
- $a nádorový supresorový protein p53 $x chemie $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šebest, Peter $7 xx0214723
- 700 1_
- $a Pečinka, Petr, $d 1964- $7 mzk2008442837
- 700 1#
- $a Tichá, Olga. $7 xx0199420
- 700 1_
- $a Němcová, Kateřina $7 xx0100595
- 700 1_
- $a Brázdová, Marie $7 xx0100610
- 700 1_
- $a Brázdová Jagelská, Eva $7 xx0098364
- 700 1_
- $a Brázda, Václav, $d 1970- $7 nlk20010096077
- 700 1_
- $a Fojta, Miroslav, $d 1967- $7 xx0060599
- 773 0_
- $w MED00009307 $t Biochemical and biophysical research communications $x 1090-2104 $g Roč. 393, č. 4 (2010), s. 894-899
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20175992 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20170626104416 $b ABA008
- 999 __
- $a ok $b bmc $g 947207 $s 782511
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 393 $c 4 $d 894-899 $e 20100220 $i 1090-2104 $m Biochemical and biophysical research communications $n Biochem Biophys Res Commun $x MED00009307
- LZP __
- $a Pubmed-20120816/10/02